Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - PHASERX, INC. | v453936_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 28, 2016
PhaseRx, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-37772 | 20-4690620 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 410 W. Harrison Street, Suite 300 Seattle, Washington |
98119 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (206) 805-6300
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On November 28, 2016, the Company issued a press release announcing Orphan Drug Designation for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press release, dated November 28, 2016 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PhaseRx, Inc. | ||
| Date: November 28, 2016 | By: | /s/ Robert W. Overell |
| Robert W. Overell, Ph.D. | ||
| Chief Executive Officer | ||